Evidence map›Paper›PMID 36715009›Full record

ArticleHuman vaccines & immunotherapeutics2023

Influenza vaccine coverage in 6months-64 years-old patients affected by chronic diseases: A retrospective cohort study in Italy.

Francesco Paolo Bianchi, Pasquale Stefanizzi, Eustachio Cuscianna, Antonio Di Lorenzo, Giovanni Migliore, Silvio Tafuri, Cinzia Annatea Germinario

Open access · goldAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Francesco Paolo BianchiInterdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy.ORCID 0000-0002-9659-0193
Pasquale StefanizziInterdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy.
Eustachio CusciannaInterdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy.
Antonio Di LorenzoInterdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy.
Giovanni MiglioreHealth Direction, Bari Policlinico University General Hospital, Bari, Italy.
Silvio TafuriInterdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy.ORCID 0000-0003-4194-0210
Cinzia Annatea GerminarioInterdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy.
University of Bari Aldo Moro · ITAzienda Universitaria Ospedaliera Consorziale - Policlinico Bari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At the beginning of each flu season, the Italian Ministry of Health defines the categories at higher risk of influenza complications, for which vaccination is actively and freely offered. The vaccine coverage (VC) of the influenza vaccine in subjects from 6 months to 64 years of age suffering from diseases that increase the risk of complications from influenza during the 2020-2021 season was evaluated. Our study wants to evaluate the VCs of the influenza vaccine in these subjects during the 2020/2021 season in Apulia. The digital archives relative to the Apulian population were used. A retrospective cohort study design was performed. 484,636 Apulian residents aged between 6 months and 64 years suffered from at least one chronic disease; 139,222 of 484,636 subjects received the influenza vaccine (VC: 28.7%) from October 2020 to January 2021. Considering the single comorbidities, the greatest values are found for pathologies for which major surgical interventions are planned and chronic renal failure/adrenal insufficiency patients, while the worst for chronic liver diseases and pathologies for which major surgical interventions are planned. In any case, it would seem that better VC is achieved in subjects with more than one chronic condition. Influenza vaccination must be promoted as a central public health measure, also because by reducing the burden on hospitals, it can greatly benefit the management of COVID-19 patients. Greater efforts by public health institutions must be implemented in order to achieve better VC in the target categories, including chronic patients.

Indexed as

COVID-19Influenza, HumanInfluenza VaccinesChronic DiseaseHumansInfantItalyRetrospective StudiesSeasonsVaccinationInfluenza Vaccinescause–effect relationshipchronic diseaseCOVID-19fluinfluenza vaccineprevention

Identifiers

PMID36715009
PMCPMC10012954
OpenAlexW4318542826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.